| CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. | |
| | |
MedLine Citation:
|
PMID: 21288102 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
To the Editor: Paré et al. (Oct. 28 issue)(1) report that among genotyped patients with acute coronary syndromes or atrial fibrillation, the effects of clopidogrel were consistent irrespective of the loss-of-function CYP2C19*2 allele, whereas gain-of-function CYP2C19*17 carriers with acute coronary syndromes benefited. Unlike these predominantly noninterventionally treated patients, loss-of-function genotypes may play a role in high-risk groups throughout the peri-interventional phase in patients with acute coronary syndromes.(2) Current predictive models including the CYP2C19*2 polymorphism and nongenetic risk factors still explain only about 12% of variability of clopidogrel responsiveness,(3),(4) but they may have an increasing role after . . . |
| | |
Authors:
|
Tobias Geisler; Boris Bigalke; Matthias Schwab |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The New England journal of medicine Volume: 364 ISSN: 1533-4406 ISO Abbreviation: N. Engl. J. Med. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-02-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 481-2 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CYP2C19 Genotype and Outcomes of Clopidogrel Treatment.
Next Document: Endometriosis-associated ovarian carcinomas.